Firefly Neuroscience (NASDAQ:AIFF) Announces Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) released its earnings results on Tuesday. The company reported ($0.16) earnings per share for the quarter, Zacks reports. The business had revenue of $0.41 million during the quarter. Firefly Neuroscience had a negative return on equity of 319.00% and a negative net margin of 2,705.88%.

Firefly Neuroscience Stock Performance

Shares of AIFF stock traded down $0.03 on Wednesday, hitting $2.16. 1,789,860 shares of the stock traded hands, compared to its average volume of 10,156,541. Firefly Neuroscience has a twelve month low of $0.62 and a twelve month high of $4.51. The firm’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.66. The stock has a market capitalization of $30.64 million, a PE ratio of -1.03 and a beta of 1.92.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Firefly Neuroscience in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Firefly Neuroscience

A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Firefly Neuroscience in the 4th quarter valued at about $53,000. Geode Capital Management LLC raised its position in shares of Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after buying an additional 58,067 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after buying an additional 401,085 shares during the period. 4.96% of the stock is owned by hedge funds and other institutional investors.

About Firefly Neuroscience

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.